Abrégé

The invention relates to compounds according to Formula (I): The invention relates to compounds according to Formula (I): wherein A is—As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, —CH2NH, —NHCOCH3, —NHCOCH2X or NO, and X is a halogen; R5 is —NHCH2COOH, OH or OR6, wherein R6 is a C1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• A61P 35/00 - Agents anticancéreux
• C07F 9/78 - Composés organo-arséniés aromatiques contenant des groupes amine

Abrégé

A vaccine composition comprising an immunogen comprising one or more SAP components or at least one nucleic acid encoding one or more SAP components; and an expression vector that encodes a chimeric CD40L polypeptide or functional equivalent thereof.

Classes IPC  ?

• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• C12N 15/86 - Vecteurs viraux

Abrégé

The disclosure relates to a radiolabelled conjugate of a trivalent arsenical compound, the use of such a radiolabelled conjugate in the diagnosis and treatment of conditions associated with cell death, such as neoplastic conditions, and processes for preparing such a radiolabelled conjugate.

Classes IPC  ?

• A61K 51/04 - Composés organiques

Abrégé

The present invention relates to a system for evolving a target biomolecule, methods of using such system and composition comprising said system.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/86 - Vecteurs viraux
• C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p. ex. bibliothèques de gènes

Abrégé

The present disclosure relates generally to the use of agents, such as oligonucleotides, to improve, increase, restore or retain the integrity of the blood brain barrier; and/or to reduce the deposition or accumulation of and/or promote the clearance of, amyloid-β. The disclosure also related to agents, such as oligonucleotides, that increase, promote or restore the level or amount of VE-cadherin in a cell, and are thus useful in the methods of the present disclosure. The present disclosure also relates to the use of such agents to treat diseases and conditions associated with damage to the blood brain barrier, including diseases and conditions associated with neuroinflammation and neurodegeneration, as well as diseases and conditions associated with amyloid-β deposition, including Alzheimer's disease (AD), Cerebral amyloid angiopathy (CAA), Lewy body dementia (LBD) and traumatic brain injury (TBI).

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present disclosure relates to a novel adeno-associated virus (AAV) receptor capable of modulating adeno-associated virus (AAV) infection or transduction of cells. The present disclosure also relates to uses of the receptor for enhancing the permissiveness of cells to AAV infection or transduction, for increasing the efficiency of transduction of AAV vectors, for enhancing AAV vector-mediated transgene transfer to cells, and for reducing the therapeutic dose of AAV vectors in gene therapy.

Classes IPC  ?

• C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to compounds according to Formula (I): 1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• A61P 35/00 - Agents anticancéreux
• C07F 9/78 - Composés organo-arséniés aromatiques contenant des groupes amine

Abrégé

The invention relates to compounds according to Formula (I) wherein A is —As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, —CH2NH, —NHCOCH3, —NHCOCH2X or NO, and X is a halogen; R5 is —NHCH2COOH, OH or OR6, wherein R6 is a C1-5 straight or branched alkyl group; and Z is a therapeutic radioisotope, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to therapeutic methods utilizing said compounds. The invention further relates to processes for preparing compounds according to Formula (I) wherein Z is a radioisotope. The invention relates to compounds according to Formula (I) wherein A is —As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, —CH2NH, —NHCOCH3, —NHCOCH2X or NO, and X is a halogen; R5 is —NHCH2COOH, OH or OR6, wherein R6 is a C1-5 straight or branched alkyl group; and Z is a therapeutic radioisotope, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to therapeutic methods utilizing said compounds. The invention further relates to processes for preparing compounds according to Formula (I) wherein Z is a radioisotope.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• A61P 35/00 - Agents anticancéreux

Abrégé

The disclosure relates to a radiolabelled conjugate of a trivalent arsenical compound, the use of such a radiolabelled conjugate in the diagnosis and treatment of conditions associated with cell death, such as neoplastic conditions, and processes for preparing such a radiolabelled conjugate.

Classes IPC  ?

• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61K 51/04 - Composés organiques
• A61K 51/08 - Peptides, p. ex. protéines
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to compounds according to Formula (I) wherein A is —As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, —CH2NH, —NHCOCH3, —NHCOCH2X or NO, and X is a halogen; R5 is —NHCH2COOH, OH or OR6, wherein R6 is a C1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• C07F 9/78 - Composés organo-arséniés aromatiques contenant des groupes amine
• A61P 35/00 - Agents anticancéreux

Abrégé

2123422325261-51-5 straight or branched alkyl group; and Z is a therapeutic radioisotope, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to therapeutic methods utilizing said compounds. The invention further relates to processes for preparing compounds according to Formula (I) wherein Z is a radioisotope.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• A61K 51/08 - Peptides, p. ex. protéines
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed are methods for inducing and generation of neutralising antibodies against SARS-CoV-2 in a subject, comprising administering to the subject an immunogenic formulation comprising an attenuated Mycobacterium bovis (BCG) strain and at least one antigen from SARS-CoV-2. Specifically, in addition to the attenuated Mycobacterium bovis (BCG) strain and the spike protein from SARS-CoV-2, the immunogenic formulations can also comprise an additional adjuvant such as aluminium hydroxide, delta inulin, or a combination of delta inulin and CpG dinucleotides (Advax).

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

22342232526 1-5 1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.

Classes IPC  ?

• C07D 255/02 - Composés hétérocycliques contenant des cycles comportant trois atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par les groupes non condensés avec d'autres cycles
• A61K 49/04 - Préparations de contraste pour rayons X
• A61K 49/10 - Composés organiques
• C07F 9/66 - Composés de l'arsenic

Abrégé

The present disclosure relates to a novel murine parvovirus, sequences encoded thereby, and applications therefor. In one embodiment the disclosure provides a method for detecting the presence of a parvovirus in a sample, comprising detecting one or more nucleic acids or polypeptides derived from the parvovirus, or antibodies against the parvovirus, in the sample. Also provided are vectors and host cells comprising sequences encoded by the parvovirus and related sequences. Also provided are animal models of kidney disease associated with infection by the parvovirus.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/86 - Vecteurs viraux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés

Abrégé

The present disclosure relates to a novel murine parvovirus, sequences encoded thereby, and applications therefor. In one embodiment the disclosure provides a method for detecting the presence of a parvovirus in a sample, comprising detecting one or more nucleic acids or polypeptides derived from the parvovirus, or antibodies against the parvovirus, in the sample. Also provided are vectors and host cells comprising sequences encoded by the parvovirus and related sequences. Also provided are animal models of kidney disease associated with infection by the parvovirus.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention provides methods for increasing the sensitivity of a tumour to immunotherapy, chemotherapy or radiotherapy by administering an effective amount of an oligonucleotide that inhibits the binding of miR-27a, or a variant thereof, to its target mRNA. Oligonucleotides used in the invention are typically in the form of a blockmirs used as an adjunctive therapy to inhibit tumour growth, normalise and/or improve function of tumour vasculature, and/or promote immune cell infiltration of tumours.

Classes IPC  ?

• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present invention provides oligonucleotides that inhibit the binding of miR-27a to VE-cadherin mRNA, particularly in the form of blockmirs. The invention also provides compositions comprising such oligonucleotides and methods of use of such oligonucleotides to modulate the activity of VE-cadherin, inhibit or reduce vascular permeability, treat or prevent a vascular permeability-associated disease or condition, inhibit tumour growth, treat ischaemic injury, enhance recovery from ischaemic injury, treat surgical wounds and/or promotes post-operative recovery, and promote or induce angiogenesis.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 7/10 - Agents antiœdémateuxDiurétiques
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to the identification of antigens, including Mycobacterium sulphate assimilation pathway components such as CysD, for preventing and treating Mycobacterium infection, especially but not exclusively Mycobacterium tuberculosis infection; to expression systems including live Mycobacterium for expression of said antigens for prevention and treatment of said infection; and to use of said antigens and expression systems for prevention and treatment of said infection.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/53 - Oxydoréductases (1)
• C12N 15/54 - Transférases (2)
• C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines
• C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
• C07K 19/00 - Peptides hybrides
• A61K 38/44 - Oxydoréductases (1)
• A61K 38/45 - Transférases (2)
• A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose

Abrégé

The present invention relates to methods for modulating angiogenesis, comprising administering to a subject, or cells or tissue derived therefrom: (i) one or more miRNA, or precursors or variants thereof, wherein at least one of said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to inhibit angiogenesis; or (ii) one or more antagonists of a miRNA, wherein said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to promote or induce angiogenesis. Also provided are methods of diagnosis of conditions associated with abnormal angiogenesis, or determining predisposition thereto. Suitable pharmaceutical compositions are also provided.

Classes IPC  ?

• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 15/79 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester

Abrégé

Provided herein are methods for diagnosing cancer disease states and determining the efficacy of cancer treatments in subjects, the methods utilising a determination of expression levels of SENEX polypeptides or SENEX-encoding nucleic acid molecules.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided herein are methods for regulating whether a cell undergoes apoptosis or senescence, comprising modulating the level of expression an/or activity of SENEX in the cell, wherein increasing the expression and/or activity of SENEX relative to normal endogenous levels induces cellular senescence and decreasing the expression and/or activity of SENEX relative to normal endogenous levels induces apoptosis. Methods for the diagnosis and treatment of senescence-associated and apoptosis-associated disorders are also provided.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to methods for modulating angiogenesis, comprising administering to a subject, or cells or tissue derived therefrom: (i) one or more miRNA, or precursors or variants thereof, wherein at least one of said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to inhibit angiogenesis; or (ii) one or more antagonists of a miRNA, wherein said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to promote or induce angiogenesis. Also provided are methods of diagnosis of conditions associated with abnormal angiogenesis, or determining predisposition thereto. Suitable pharmaceutical compositions are also provided.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to the prevention and treatment of metabolic abnormalities characterized by abnormal glucose metabolism, including diabetes mellitus and new onset diabetes mellitus through the use of fibroblast activation protein (FAP) selective inhibitors.

Classes IPC  ?

• A61K 31/275 - NitrilesIsonitriles
• A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
• A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
• C07D 211/60 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
• A61K 31/69 - Composés du bore
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• C07D 277/06 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
• A61K 31/401 - ProlineSes dérivés, p. ex. captopril
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• C07D 205/02 - Composés hétérocycliques comportant des cycles à quatre chaînons ne contenant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles
• C07F 5/02 - Composés du bore
• A61K 31/426 - 1,3-Thiazoles
• A61P 3/06 - Antihyperlipémiants
• C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07F 9/02 - Composés du phosphore

Abrégé

The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present disclosure relates to compounds and methods for inhibiting the formation of miRNAs that inhibit translation of one or more identified proteins. The compounds comprise antisense oligonucleotides targeting the ph-miRNA precursor of miRNAs.

Classes IPC  ?

• A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide